4-(1-hydroxy-1-methylethyl)-3-fluoropyridine | 87674-13-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-(1-hydroxy-1-methylethyl)-3-fluoropyridine
• 英文别名: 2-(3-fluoropyridin-4-yl)propan-2-ol；4-Pyridinemethanol, 3-fluoro-alpha,alpha-dimethyl-
• CAS: 87674-13-3
• 化学式: C₈H₁₀FNO
• 分子量: 155.172
• InChiKey: JNJKMILXZXZFDW-UHFFFAOYSA-N

物化性质

• 沸点：
  90 °C(Press: 16 Torr)
• 密度：
  1.153±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(1-hydroxy-1-methylethyl)-3-fluoropyridine 在 盐酸 、 正丁基锂 、 碘代三甲硅烷 、 磷化氢 、 氢碘酸 、 间氯过氧苯甲酸 、 肼 、 三氯氧磷 、 2-碘酰基苯甲酸 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 氯仿 、 水 、 乙二醇 、 二甲基亚砜 、 甲苯 为溶剂， 反应 76.0h， 生成 1-(2,6-Dichloropyridin-4-yl)-3-[[3-(3-hydroxypropyl)-1-methyl-7-propan-2-ylpyrazolo[4,3-b]pyridin-5-yl]amino]urea
  参考文献：
  名称：

  新規なスフィンゴシン１‐リン酸受容体アンタゴニスト

  摘要：

  This invention includes a sphingosine-1-phosphate receptor 2 (S1P2) antagonist of formula (I), wherein R1 is -CH2CH=CH2, -CH3, or -CH2CH2CH2OH, R2 is -H, -CH2CO2H, -CH2CH2OH, -CH2CH2CH2OH, -CH2CONH2, or -CH2CO2Et, and R3 is 4-substituted-2,6-dichloropyridine, 4-substituted-2-chloro-6-hydroxyethylpyridine, 4-substituted-2-chloro-6-hydroxypropylpyridine, 4-substituted-2-(aminoethyl)-6-chloropyridine, 4-substituted-2-(aminoethylmethyl)-6-chloropyridine, or 5-substituted-2,3-dichlorothiophene. It is disclosed that a pharmaceutical composition containing a sphingosine-1-phosphate S1P2 receptor antagonist receptor is useful in the treatment of ocular tumors and blindness, as well as fibrotic lung, kidney, liver, and skin diseases.【No selection figure】

  公开号：

  JP2015524789A
• 作为产物：
  描述：

  3-氟吡啶 、 丙酮 在 正丁基锂 、 四甲基乙二胺 作用下， 生成 4-(1-hydroxy-1-methylethyl)-3-fluoropyridine
  参考文献：
  名称：

  π缺陷杂芳族化合物的金属化综述：3-氟吡啶的区域选择性邻位锂化：指导作用及其在2,3-或3,4-二取代吡啶的合成中的应用

  摘要：

  首先综述了π缺陷杂环化合物的金属化，这表明了该研究领域的重要进展。然后通过研究3-氟吡啶金属化区域选择性来给出该反应的特定方面。

  DOI：

  10.1016/s0040-4020(01)91919-2

文献信息

• [EN] NOVEL SPHINGOSINE 1-PHOSPHATE RECEPTOR ANTAGONISTS<br/>[FR] NOUVEAUX ANTAGONISTES DE RÉCEPTEUR DE SPHINGOSINE 1-PHOSPHATE
  申请人：SWENSON ROLF ERIC

  公开号：WO2014158302A1

  公开（公告）日：2014-10-02

  The present invention relates to sphingosine-1 -phosphate (S1 P) receptors and compounds of the general formula (1), that are useful in the treatment and prevention of conditions associated with such receptors. More specifically, the present invention relates to the synthesis and use of sphingosine 1 -phosphate receptor 2 (S1 P2) antagonists that are useful in the treatment of cancer, atherosclerosis, diabetic retinopathy, and other inflammatory diseases. Among these inflammatory diseases that could be treated with these S1 P2 antagonist are those characterized by fibrosis including chronic lung disease, chronic kidney and liver disease, chronic heart disease, and skin diseases such as sclerosis/scleroderma. The S1 P2 antagonists can also be used in the treatment of glioblastoma multiforme (brain cancer), pediatric neuroblastoma, and other cancers.

  本发明涉及鞘氨醇-1-磷酸（S1P）受体和一般式（1）的化合物，这些化合物在与这些受体相关的疾病的治疗和预防中是有用的。更具体地，本发明涉及合成和使用鞘氨醇-1-磷酸受体2（S1P2）拮抗剂，这些拮抗剂在癌症、动脉粥样硬化、糖尿病视网膜病变和其他炎症性疾病的治疗中是有用的。这些炎症性疾病中可以用这些S1P2拮抗剂治疗的包括以纤维化为特征的疾病，如慢性肺病、慢性肾脏和肝脏疾病、慢性心脏病，以及硬化/硬皮病等皮肤病。S1P2拮抗剂还可用于治疗多形性胶质母细胞瘤（脑癌）、儿童神经母细胞瘤和其他癌症。
• [EN] CONDENSED RING PYRIDINE COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-2 (S1P2) RECEPTORS<br/>[FR] COMPOSÉS PYRIDINES À NOYAUX CONDENSÉS COMME MODULATEURS SÉLECTIFS D'UN SOUS-TYPE DES RÉCEPTEURS DE LA SPHINGOSINE-1-PHOSPHATE-2 (S1P2)
  申请人：ALLERGAN INC

  公开号：WO2011041287A1

  公开（公告）日：2011-04-07

  The invention provides compounds represented by the formula I, each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity, wherein these compounds selected from the group consisting of wherein A, B, C, D, X, Y, Z and R3 are defined in the specification. Said compounds are useful for treating a disease or condition of a mammal selected from the group consisting of ocular diseases; systemic vascular barrier related diseases; allergies and other inflammatory diseases; cardiac diseases or conditions; fibrosis; pain and wounds.

  该发明提供了由公式I表示的化合物，其中每个化合物可能具有鞘氨醇-1-磷酸受体激动剂和/或拮抗剂生物活性，这些化合物选自由A、B、C、D、X、Y、Z和R3定义的组成的组中。所述化合物适用于治疗从眼部疾病；全身血管屏障相关疾病；过敏和其他炎症性疾病；心脏疾病或症状；纤维化；疼痛和伤口中选择的哺乳动物的疾病或症状。
• Condensed Ring Pyridine Compounds As Subtype-Selective Modulators Of Sphingosine-1-Phosphate-2 (S1P2) Receptors
  申请人：Fang Wenkiu K.

  公开号：US20120208840A1

  公开（公告）日：2012-08-16

  The invention provides compounds represented by the formula I, each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity, wherein these compounds selected from the group consisting of wherein A, B, C, D, X, Y, Z and R 3 are defined in the specification. Said compounds are useful for treating a disease or condition of a mammal selected from the group consisting of ocular diseases; systemic vascular barrier related diseases; allergies and other inflammatory diseases; cardiac diseases or conditions; fibrosis; pain and wounds.

  该发明提供了由公式I表示的化合物，每个化合物都可能具有鞘氨醇-1-磷酸受体激动剂和/或拮抗剂生物活性，其中这些化合物选自由A、B、C、D、X、Y、Z和R3定义的组中。这些化合物可用于治疗哺乳动物的疾病或病况，所述哺乳动物的疾病或病况选自眼部疾病；系统性血管屏障相关疾病；过敏和其他炎症性疾病；心脏疾病或病况；纤维化；疼痛和伤口。
• Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (S1P2) receptors
  申请人：Fang Wenkiu K.

  公开号：US08507682B2

  公开（公告）日：2013-08-13

  The invention provides compounds represented by the formula I, each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity, wherein these compounds selected from the group consisting of wherein A, B, C, D, X, Y, Z and R3 are defined in the specification. Said compounds are useful for treating a disease or condition of a mammal selected from the group consisting of ocular diseases; systemic vascular barrier related diseases; allergies and other inflammatory diseases; cardiac diseases or conditions; fibrosis; pain and wounds.

  本发明提供一种由式I所表示的化合物，该化合物可能具有鞘氨醇-1-磷酸受体激动剂和/或拮抗剂的生物活性，所述化合物选自由式A、B、C、D、X、Y、Z和R3所定义的化合物组中。所述化合物可用于治疗哺乳动物的疾病或病况，所述疾病或病况选自眼部疾病、系统性血管屏障相关疾病、过敏和其他炎症性疾病、心脏疾病或病况、纤维化、疼痛和伤口。
• Novel Sphingosine 1-Phosphate Receptor Antagonists
  申请人：SWENSON Rolf E.

  公开号：US20150045332A1

  公开（公告）日：2015-02-12

  The present invention relates to sphingosine-1-phosphate (S1P) receptors and compounds of the general formula: that are useful in the treatment and prevention of conditions associated with such receptors. More specifically, the present invention relates to the synthesis and use of sphingosine 1-phosphate receptor 2 (S1P 2 ) antagonists that are useful in the treatment of cancer, atherosclerosis, diabetic retinopathy, and other inflammatory diseases. Among these inflammatory diseases that could be treated with these S1P 2 antagonist are those characterized by fibrosis including chronic lung disease, chronic kidney and liver disease, chronic heart disease, and skin diseases such as sclerosis/scleroderma. The S1P 2 antagonists can also be used in the treatment of glioblastoma multiforme (brain cancer), pediatric neuroblastoma, and other cancers.

  本发明涉及鞘氨醇-1-磷酸（S1P）受体和下列通式的化合物： 这些化合物在治疗和预防与此类受体相关的疾病方面是有用的。更具体地，本发明涉及合成和使用鞘氨醇1-磷酸受体2（S1P2）拮抗剂，这些拮抗剂在治疗癌症、动脉硬化、糖尿病视网膜病变和其他炎症性疾病方面是有用的。这些炎症性疾病中，可以用这些S1P2拮抗剂治疗那些以纤维化为特征的疾病，包括慢性肺病、慢性肾脏和肝脏疾病、慢性心脏病以及硬化/硬皮病等皮肤疾病。S1P2拮抗剂还可以用于治疗多形性胶质母细胞瘤（脑癌）、儿童神经母细胞瘤和其他癌症。